Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 1/20 | 0.55 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.53 |
| ▸ | ITGB1 | P05556 | 10/20 | 0.52 |
| ▸ | ITGA4 | P13612 | 10/20 | 0.52 |
| ▸ | ITGB7 | P26010 | 5/20 | 0.52 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.52 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.48 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.48 |
| ▸ | ITGAL | P20701 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11056940 | 0.89 | ALDH1A1 (0.49) | TYK2ITGB1ITGA4ALDH1A1POLB | |
| Water SCHEMBL7924276 | 0.87 | TAS1R3 (0.47) | TYK2ITGB1ITGA4ALDH1A1POLB | |
| SCHEMBL1926917 | 0.87 | L3MBTL1 (0.54) | ITGB2ICAM1ITGALALDH1A1HPGD | |
| SCHEMBL14500983 | 0.85 | ITGB1 (0.55) | TYK2UTS2RITGB1ITGA4ITGB7 | |
| SCHEMBL18885328 | 0.81 | ITGB2 (0.58) | TYK2ITGB2ICAM1ITGALALDH1A1 | |
| SCHEMBL551795 | 0.80 | PBRM1 (0.49) | ITGB1ITGA4ITGB2ICAM1ITGAL | |
| SCHEMBL25607327 | 0.79 | ITGB1 (0.47) | ITGB1ITGA4ITGB2ICAM1ITGAL | |
| SCHEMBL7852285 | 0.79 | TSHR (0.43) | TYK2ALDH1A1POLBHPGDL3MBTL1 | |
| SCHEMBL4370150 | 0.79 | TYK2 (0.58) | TYK2UTS2RITGB1ITGA4ITGB7 | |
| SCHEMBL5022094 | 0.78 | TYK2 (0.57) | TYK2ITGB1ITGA4ITGB7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208968-A1 | ALPHA V BETA 6 AND ALPHA V BETA 1 INTEGRIN INHIBITORS AND USES THEREOF | DICE MOLECULES SV, INC. | 2024-06-27 | — | — | US | disclosed |
| US-20230159446-A1 | Methods and Compositions for Targeting Tregs using CCR8 Inhibitors | NANJING IMMUNOPHAGE BIOMEDICAL CO., LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20230038589-A1 | Methods and compositions for targeting Tregs using CCR8 inhibitors | Nanjing Immunophage Biotech Co., Ltd. (CN) | 2023-02-09 | — | — | US | disclosed |
| US-20170137407-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2017-05-18 | — | — | US | disclosed |
| US-20170137407-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2017-05-18 | — | — | US | disclosed |
| US-9546180-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| US-9546180-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| US-9115141-B2 | Substituted isoquinolinones and methods of treatment thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-9115141-B2 | Substituted isoquinolinones and methods of treatment thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-20140288048-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2014-09-25 | — | — | US | disclosed |
| US-20140288048-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS, INC. | 2014-09-25 | — | — | US | disclosed |
| US-8785470-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8785470-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| WO-2013032591-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS INC. (US) | 2013-03-07 | — | — | WO | disclosed |
| US-20130053362-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLKINE, LLC (US) | 2013-02-28 | — | — | US | disclosed |
| US-20130053362-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLKINE, LLC (US) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288048-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AKT3, PIK3CA, AKT1 | TYK2 597/4885UTS2R 4335/4885ITGB1 3082/4885 |
| US-20240208968-A1 | ALPHA V BETA 6 AND ALPHA V BETA 1 INTEGRIN INHIBITORS AND USES THEREOF | ITGB1, ITGA1, ITGAV | TYK2 946/4885UTS2R 2825/4885ITGB1 1/4885 |
| US-20230159446-A1 | Methods and Compositions for Targeting Tregs using CCR8 Inhibitors | CCR8, CCR1, CCR3 | TYK2 2115/4885UTS2R 1436/4885ITGB1 1209/4885 |
| US-20130053362-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AKT3, PIK3CA, AKT1 | TYK2 597/4885UTS2R 4335/4885ITGB1 3082/4885 |
| US-20170137407-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AKT3, PIK3CA, AKT1 | TYK2 597/4885UTS2R 4335/4885ITGB1 3082/4885 |
| US-20230038589-A1 | Methods and compositions for targeting Tregs using CCR8 inhibitors | CCR8, CCR1, CCR3 | TYK2 2115/4885UTS2R 1436/4885ITGB1 1209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.